From Animal Models to NAMs-driven AI Tools

• April 30, 2025

FDA’s QIDP Designation: The Game-Changer in Antimicrobial Drug Innovation

• April 23, 2025

RMAT-The Regulatory Catalyst for Accelerating Regenerative Medicine Therapies

• April 16, 2025

What is an INTERACT Meeting

• April 2, 2025

Understanding Protocol Deviations for Clinical Investigations in the US

• March 19, 2025

Trump’s Drug Tariff Shockwave: Disruption and Reshaping of Global Pharmaceutical Supply Chains

• March 12, 2025

Navigating the Future: AI in the Drug Product Life Cycle and Regulatory Landscape

• February 26, 2025

FDA Accelerated Programs in Drug Development

• February 13, 2025

PMDA Phase1 Waiver Guidelines for Japanese Participation in Global MRCTs

• February 7, 2025

Leadership and Policy Shifts in U.S. Healthcare: Potential Impacts on the Biopharma Industry

• January 31, 2025